Refractory scirrhous gastric cancer accounts for about 10% of all gastric cancers and affects thousands of people annually.Current treatments have been inadequate for scirrhous gastric cancer, which grows rapidly and metastasizes frequently.The research group has clarified that normal stromal cells (fibroblasts, endothelial cells, immune cells, etc.) are involved in the proliferation and metastasis of Skills gastric cancer cells, but the mechanism by which cancer tissue induces normal stromal cells, etc. , The details were unknown.

　This time, the research group worked on the elucidation of normal stromal cell induction signals of scirrhous gastric cancer using a mouse model.As a result, Skills gastric cancer cells produce a bone marrow cell inducer (chemokine CXCL1) to induce normal bone marrow cells into the cancer tissue, and bone marrow-derived normal cells gathered around the cancer cells increase the strength of the cancer cells. Clarified.Furthermore, administration of a signal inhibitor (a small molecule compound substance that inhibits signal transduction of the CXCL1 receptor CXCR2) to a bone marrow cell inducer suppresses the accumulation of bone marrow cells in cancer and reduces the growth and metastasis of scirrhous gastric cancer. The treatment was successful.This revealed that CXCL1 / CXCR2 is a bone marrow-derived cell-inducing signal and is effective as a therapeutic agent.

　Based on this result, if a therapeutic drug targeting the CXCL1 / CXCR2 signal is developed, the treatment results for gastric cancer are expected to improve dramatically.Furthermore, the research group has confirmed that the CXCL1 / CXCR2 signal is also found in intractable cancers such as pancreatic cancer, and treatments targeting CXCL1 / CXCR2 can be expected as new treatments for many intractable cancers.